Visx
This article was originally published in The Gray Sheet
Executive Summary
Financier Carl Icahn forgoes earlier plan to elect a rival slate of directors to the firm's board at the May 2002 annual meeting (1"The Gray Sheet" Nov. 26, 2001, p. 30). In a recent 13D filing with the Securities & Exchange Commission, Icahn maintained that depending upon market conditions, he may acquire or dispose of additional shares. Icahn previously proposed to acquire Visx for $32 per share in a hostile takeover bid last April...
You may also be interested in...
Icahn Renews Effort To Replace Visx Board At Next Shareholder Meeting
Financier Carl Icahn appears to have abandoned his $32 a share cash tender offer for Visx in favor of electing a rival slate of directors to the firm's board, a strategy that in the past has failed
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.